Abstract
Both type I and type II diabetes are common diseases with no cure. Both are characterised by chronic hyperglycaemia and can be managed, at least to some extent, by daily proteins treatments. However, in both cases, administration of the protein does not always control glucose levels in a physiologically normal time frame. A variety of different approaches to restore lost insulin in type 1 diabetes by gene therapy have recently been described. Strategies to induce production of new β cells, ameliorate or evade the auto-immune response that leads to β cell destruction, or simply delivering a modified insulin cDNA under the control of glucose-responsive promoters have all resulted in restoration of euglycaemia in a physiologically normal time frame in rodent models of diabetes. In terms of application of gene therapy to type 2 diabetes, delivery of a single protein using a virus vector can also restore euglycaemia in vivo. In addition to these advances, new technologies to permanently modify the genome which could be adapted for the long-term treatment of diabetes are described.
Keywords: gene therapy, euglycaemia restoration, gene delivery, gene replacement therapy, virus vectors, glucose-responsive promoters
Infectious Disorders - Drug Targets
Title: Application of Gene Therapy in Diabetes Care
Volume: 8 Issue: 2
Author(s): Patrick T. Harrison
Affiliation:
Keywords: gene therapy, euglycaemia restoration, gene delivery, gene replacement therapy, virus vectors, glucose-responsive promoters
Abstract: Both type I and type II diabetes are common diseases with no cure. Both are characterised by chronic hyperglycaemia and can be managed, at least to some extent, by daily proteins treatments. However, in both cases, administration of the protein does not always control glucose levels in a physiologically normal time frame. A variety of different approaches to restore lost insulin in type 1 diabetes by gene therapy have recently been described. Strategies to induce production of new β cells, ameliorate or evade the auto-immune response that leads to β cell destruction, or simply delivering a modified insulin cDNA under the control of glucose-responsive promoters have all resulted in restoration of euglycaemia in a physiologically normal time frame in rodent models of diabetes. In terms of application of gene therapy to type 2 diabetes, delivery of a single protein using a virus vector can also restore euglycaemia in vivo. In addition to these advances, new technologies to permanently modify the genome which could be adapted for the long-term treatment of diabetes are described.
Export Options
About this article
Cite this article as:
Harrison T. Patrick, Application of Gene Therapy in Diabetes Care, Infectious Disorders - Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152608784746493
DOI https://dx.doi.org/10.2174/187152608784746493 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs
Current Chemical Biology The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Concise Synthesis of Benzoindolizidine Derivatives and Bioactivity Evaluation
Letters in Organic Chemistry Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets Protein Phosphatase 2A as a Potential Target for Treatment of Adult T Cell Leukemia
Current Cancer Drug Targets Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Current Signal Transduction Therapy